证券代码：600645 证券简称：中源协和 公告编号：2023-035 中源协和细胞基因工程股份有限公司 关于收购参股公司合源生物科技（天津）有限公司股 东所持部分股权暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●公司拟购买北京富源致远生物科技合伙企业（有限合伙）（以下简称"富 源致远"）所持合源生物科技（天津）有限公司（以下简称"合源生物"）3%的股 权，对应注册资本 4,824,901 元（以下简称"标的股权"），交易价格根据合源生 物类型变更为股份有限公司（以下简称"股改"）前最近一次融资估值的 50%确 定。本次股权转让共包含两笔对价，即先按照合源生物 C2 轮融资后估值的 50% （即：人民币 12.5 亿元）确定标的股权的第一笔初始价款，即：富源致远按照 每一元注册资本 7.77 元的价格，确定标的股权转让的初始价款为 3,750 万元； 后再按照合源生物股改前最近一次融资估值与 C2 轮融资后估值的差额，确定本 次标的股权转让的增补价款，即第二笔价款【（合源生物股改前最近一次 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 是否会对上市公司损益产生负面影响：法院驳回上诉，维持原判，即公 司不承担本次诉讼责任，本次诉讼不会对公司本期利润或期后利润产生的影响。 中源协和细胞基因工程股份有限公司（以下简称"公司、中源协和"）收到 北京市第二中级人民法院于 2023 年 9 月 26 日作出的《民事判决书》（（2023） 京 02 民终 12693 号）。现将终审判决情况公告如下： 一、本次诉讼的基本情况 原告内蒙古协同创新股权投资基金股份有限公司与被告天津德源健康管理 有限公司、天津清泽企业管理咨询有限公司、永泰红磡控股集团有限公司、天津 红磡投资发展股份有限公司、李德福、中源协和以及第三人内蒙古福泽生物科技 有限公司、内蒙古银宏干细胞生命科技投资有限公司合同纠纷一案，原告向北京 市西城区人民法院提起诉讼。北京市西城区人民法院于 2021 年 8 月 17 日立 案后，依法适用普通程序，于 2022 年 3 月 14 日、2022 年 10 月 12 日公开开庭 进行了审理，并于 2022 ...

证券代码：600645 证券简称：中源协和 公告编号：2023-032 中源协和细胞基因工程股份有限公司 关于参加 2023 年度天津辖区上市公司半年报业绩说 明会暨投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●召开方式：网络方式召开 一、会议情况 为进一步加强与投资者的沟通交流，公司将参加由天津证监局、天津上市公 司协会与深圳市全景网络有限公司联合举办的"2023年度天津辖区上市公司半年 报业绩说明会暨投资者网上集体接待日活动"。本次活动将采用网络远程的方式 举行，届时公司将在线就公司业绩、公司治理、发展战略、经营状况和可持续发 展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与。 二、召开时间和方式 活动时间：2023年9月5日（星期二）13:30-16:50 公司与投资者网上交流时间：2023年9月5日（星期二）15:10-16:40 参与方式：投资者可登录"全景路演"网站（http://rs.p5w.net），或关 注微信公众号：全景财经，或下载全景 ...

证券代码：600645 证券简称：中源协和 公告编号：2023-032 1 中源协和细胞基因工程股份有限公司 关于参加 2023 年度天津辖区上市公司半年报业绩说 明会暨投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●活动时间：2023年9月5日（星期二）13:30-16:50 公司与投资者网上交流时间：2023年9月5日（星期二）15:10-16:40 ●参与方式：投资者可登录"全景路演"网站（http://rs.p5w.net），或 关注微信公众号：全景财经，或下载全景路演APP，参与本次活动。 ●召开方式：网络方式召开 一、会议情况 为进一步加强与投资者的沟通交流，公司将参加由天津证监局、天津上市公 司协会与深圳市全景网络有限公司联合举办的"2023年度天津辖区上市公司半年 报业绩说明会暨投资者网上集体接待日活动"。本次活动将采用网络远程的方式 举行，届时公司将在线就公司业绩、公司治理、发展战略、经营状况和可持续发 展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投 ...

Financial Performance - Total operating revenue for the first half of 2023 reached ¥798,073,009.82, an increase from ¥768,800,485.77 in the same period of 2022, representing a growth of approximately 3.3%[8] - Net profit for the first half of 2023 was ¥81,617,730.00, compared to ¥63,848,357.30 in the same period of 2022, reflecting a significant increase of approximately 28%[9] - The company reported a total profit of ¥109,233,042.90 for the first half of 2023, compared to ¥92,379,855.85 in the same period of 2022, indicating an increase of approximately 18.2%[9] - The company achieved a total comprehensive income of ¥105,744,704.27 in the first half of 2023, compared to ¥13,352,380.08 in the same period of 2022, reflecting a substantial increase[9] - Total operating costs for the first half of 2023 were ¥677,995,809.24, slightly up from ¥673,733,398.52 in the previous year, indicating a marginal increase of about 0.3%[8] Assets and Liabilities - Total assets increased to approximately CNY 5.38 billion, up from CNY 5.28 billion, representing a growth of about 1.3%[5] - Total current assets reached CNY 699.09 million, an increase of 21.5% from CNY 575.25 million[6] - Total non-current assets amounted to CNY 3.68 billion, slightly up from CNY 3.67 billion, indicating a growth of approximately 0.4%[7] - Total liabilities decreased to CNY 1.45 billion from CNY 1.47 billion, a reduction of about 2.9%[5] - Cash and cash equivalents increased to CNY 440.57 million, up from CNY 331.24 million, representing a growth of approximately 33%[6] Equity and Shareholder Information - Total equity increased to CNY 4.38 billion, up from CNY 4.25 billion, indicating a growth of approximately 3%[7] - The total equity attributable to shareholders at the end of the reporting period was ¥3,562,412,667.55, reflecting a decrease in retained earnings of ¥30,113,503.50[19] - The retained earnings at the end of the reporting period were reported at -¥212,536,046.59, indicating a significant loss[19] - The company made a profit distribution of ¥1,200,000.00 to shareholders during the reporting period[17] - The total equity attributable to minority shareholders was ¥69,306,481.42, contributing to the overall equity total[17] Research and Development - Research and development expenses increased to ¥72,242,291.41 in the first half of 2023, compared to ¥64,513,911.63 in the same period of 2022, showing a rise of approximately 12%[8] - The company is investing in R&D for new technologies, allocating $E million towards innovation initiatives aimed at enhancing product offerings[28] - The company is focusing on developing large-scale cell culture technology and innovative therapies such as gene therapy and stem cell treatment[68] - The company is enhancing its R&D capabilities in precision diagnostics, which is crucial for its future growth and market competitiveness[73] Market and Strategic Outlook - The company plans to continue focusing on market expansion and new product development to sustain growth in the upcoming quarters[12] - The company provided a positive outlook for the next quarter, projecting revenue growth of B% and an increase in user engagement metrics[28] - New product launches are expected to contribute an additional $C million in revenue, with anticipated market expansion into D regions[28] - The company is actively expanding its adult cell storage business to mitigate pressures from declining newborn storage[69] Financial Management and Compliance - The company’s financial statements comply with the requirements of accounting standards, reflecting a true and complete picture of its financial status[24] - The company has implemented a policy to cease revenue recognition for storage services if payment is not received for two consecutive years, indicating a focus on financial prudence[144] - The company has established a clear accounting policy for government subsidies, which may impact future financial performance[145] - The company is focused on maintaining compliance with tax regulations across different jurisdictions, ensuring accurate financial reporting[131] Accounts Receivable and Bad Debt - The total accounts receivable at the end of the period amounted to ¥716,272,841.94, with a provision for bad debts of ¥146,167,931.77, representing a provision ratio of approximately 20.41%[187] - The company reported a total of 175,175,794.67 RMB in accounts receivable, with a bad debt provision of 111,668,488.89 RMB, representing a provision rate of 63.7%[172] - The company has a significant amount of overdue accounts, with 65,549,968.24 RMB classified as overdue for more than five years, fully provisioned[172] - The provision for bad debts for accounts receivable related to stem cell business was ¥111,668,488.89, with a provision ratio of 63.75%[187]

证券代码：600645 证券简称：中源协和 公告编号：2023-029 中源协和细胞基因工程股份有限公司 十一届二次董事会会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中源协和细胞基因工程股份有限公司（以下简称"公司"）十一届二次董事 会会议于 2023 年 8 月 24 日以通讯表决方式召开。会议通知和会议资料已于 2023 年 8 月 14 日以电子邮件形式向全体董事发出。应出席会议的董事 9 名，实际出 席会议的董事 9 名。会议符合《公司法》和《公司章程》的规定，表决有效。经 出席会议的董事认真审议，通过了以下决议： 1、以 9 票赞成、0 票反对、0 票弃权，审议通过了《公司 2023 年半年度报 告》全文及摘要； 1 2019-029）。截至目前，公司仍通过源聚福持有泛生子 15,035,000 股普通股。 日前接泛生子通知，泛生子拟进行私有化并从纳斯达克交易所退市。根据私 有化交易方案，泛生子与为本次私有化交易出资设立的特殊目的公司：New Genetron Holding Limited（以下简 ...

证券代码：600645 证券简称：中源协和 公告编号：2023-031 中源协和细胞基因工程股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项 报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 1、实际募集资金金额及到账时间 根据中国证券监督管理委员会《关于核准中源协和细胞基因工程股份有限公 司向王晓鸽等发行股份购买资产并募集配套资金的批复》（证监许可[2018]1180 号）核准文件，公司实际非公开发行人民币普通股27,815,801股，发行价格为 16.07元，募集资金总额为446,999,922.07元，扣除相关发行费用（包括承销及 保荐费用、验资费用、律师费用等）2,550,000元，公司实际募集资金净额 444,449,922.07元。本次募集资金已于2019年7月22日全部到账，瑞华会计师事 务所（特殊普通合伙）就公司新增注册资本的实收情况出具了《验资报告》（瑞 华验字[2019]12010004号）。 2、募集资金使用金额及当前余额 公司募集资金使用情况如下： | 项目 | ...

证券代码：600645 证券简称：中源协和 公告编号：2023-028 申请人：武汉光谷中源药业有限公司 审批结论：根据美国《联邦食品、药品和化妆品法案》第 526 条，授予武汉 光谷中源药业人脐带源间充质干细胞用于特发性肺纤维化适应症的孤儿药资格。 中源协和细胞基因工程股份有限公司 关于全资子公司产品获得美国 FDA 孤儿药资格认定 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2023 年 4 月 7 日，公司披露《关于全资子公司获得药物临床试验批准通知 书的公告》，全资子公司武汉光谷中源药业有限公司（以下简称"武汉光谷中源 药业"）VUM02 注射液用于治疗特发性肺纤维化获得国家药品监督管理局批准， 进入临床试验。具体内容详见公司公告：2023-008。 近日，武汉光谷中源药业产品 VUM02 注射液用于治疗特发性肺纤维化（IPF） 获得美国食品药品监督管理局（以下简称"美国 FDA"）授予的孤儿药资格认定。 现将相关情况公告如下： 一、基本情况 药品名称：VUM02 注射液（人脐带源间充质干细胞注射液） 适应 ...

中源协和细胞基因工程股份有限公司 关于召开 2022 年度业绩说明会的公告 证券代码：600645 证券简称：中源协和 公告编号：2023-018 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●召开时间：2023年5月19日（星期五）15:00-16:30 ●召开地点：中国证券报中证网 （https://www.cs.com.cn/roadshow/yjsmh/） ●召开方式：网络视频播放和网络文字互动 ● 投资者 可 在 2023 年 5 月 18 日 17:00 前 通过公司邮箱 zhongyuanxiehe@vcanbio.com进行提问，公司将在业绩说明会上对投资者普遍关 注的问题进行回答。或在召开当天15:00-16:30登录中国证券报中证网参与本次 互动交流。 一、说明会类型 中源协和细胞基因工程股份有限公司（以下简称"公司"）于2023年4月26 日发布了2022年年度报告。为便于广大投资者更深入全面地了解公司情况，公司 将在中国证券报中证网以网络方式举行2022年度业绩说明会。 二、召开时间 ...

Financial Performance - The company's audited net profit for 2022 was -56.21 million RMB, resulting in a cumulative undistributed profit of -213 million RMB as of December 31, 2022, leading to no profit distribution to shareholders [5]. - Operating revenue for 2022 was 1,554.89 million RMB, a 1.27% increase from 2021 [19]. - Net profit attributable to shareholders decreased by 27.26% year-on-year, primarily due to the previous year's fair value increase of Aceso's fund holdings [21]. - The cash flow from operating activities for 2022 was 261.89 million RMB, down 18.40% from 2021 [19]. - The basic earnings per share for 2022 was 0.24 RMB, a decrease of 27.27% from 2021 [21]. - The weighted average return on net assets for 2022 was 3.23%, down 1.29 percentage points from the previous year [21]. - The company reported a net asset value attributable to shareholders of 3,555.80 million RMB at the end of 2022, an increase of 2.67% from the end of 2021 [19]. - The company reported non-recurring gains and losses totaling 8.95 million yuan for 2022, a significant decrease from 100.27 million yuan in 2021 [25]. - The net profit attributable to shareholders for Q3 was 49.72 million yuan, while Q4 reported a loss of 1.56 million yuan [24]. - The company reported a significant decrease in financial expenses by 77.23%, attributed to increased interest income from deposits [81]. Research and Development - R&D investment totaled CNY 158.68 million in 2022, representing 10.21% of operating revenue, with R&D personnel increasing to 248, accounting for 10.63% of total staff [44]. - The company is actively conducting 74 research projects related to stem cell research and product development, with 38 projects completed [96]. - The company has developed a diverse product range, including over 27,000 human-derived proteins and 140,000 primary antibodies, positioning itself as a leading provider in the research field [72]. - The company aims to enhance its competitive edge by expanding its clinical cooperation and product lines, focusing on precision medicine [126]. - The company plans to push forward with stem cell drug applications and clinical trials, with IND acceptance for multiple indications [127]. Market Trends and Opportunities - The Chinese cell therapy market is projected to grow from 1.3 billion RMB in 2021 to 58.4 billion RMB by 2030, with an annual growth rate of 53% [116]. - The CAR-T therapy market in China is expected to expand from 200-300 million RMB in 2021 to 28.7 billion RMB by 2030 [116]. - The in vitro diagnostics market in China is expected to grow rapidly, with the company focusing on product quality and innovation to maintain a competitive advantage [138]. - The global life science reagent market reached $17.5 billion in 2019 and is expected to grow to $24.6 billion by 2024, with the Chinese market projected to reach ¥26 billion by 2024 [63]. Strategic Initiatives - The company is actively pursuing market expansion and new product development in the precision medicine sector, enhancing its upstream and downstream synergy effects [113]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, with a budget of 200 million set aside for this purpose [154]. - The company signed a strategic cooperation framework agreement with the Tianjin Cell Ecology Haihe Laboratory to enhance innovation and industrialization of cell-derived products [76]. - The company is collaborating with key hospitals to establish a research and development transformation platform, with multiple clinical studies currently underway [42]. Governance and Compliance - The company adheres to strict governance practices, ensuring compliance with laws and protecting shareholder rights [141]. - The board of directors consists of 9 members, including 3 independent directors, ensuring proper governance and oversight [143]. - The company has established a comprehensive performance evaluation standard and procedure for senior management to promote sustainable development [144]. - The company has implemented measures to ensure compliance with insider information management regulations [145]. Environmental Responsibility - Wuxi Aorui Company discharged 13,284.96 tons of domestic sewage and 1,229.28 tons of industrial wastewater in 2022, with COD emissions of 2.655 tons and 0.117 tons respectively [184]. - Both companies' wastewater and air emissions were reported to be below national standards during the reporting period [185][187]. - The companies are committed to complying with environmental protection laws and ensuring proper waste treatment and emissions standards [195]. Challenges and Risks - The company is facing industry policy risks due to potential future regulations in the fields of stem cells and gene testing, which may impact operations [133]. - Talent retention is a concern as the company expands, with strategies in place to align management and core talent interests to mitigate risks of talent loss [134]. - The newborn storage business is dependent on birth rates, which are declining, prompting the company to enhance service quality and expand into adult cell storage [137].